Search Results - "SIEBER, Paul R"

Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer by SMITH, Matthew R, SAAD, Fred, EGERDIE, Blair, SIEBER, Paul R, TAMMELA, Teuvo L. J, CHUNLEI KE, LEDER, Benjamin Z, GOESSL, Carsten

“…To characterize changes in lean body mass (LBM) in men with prostate cancer receiving androgen-deprivation therapy (ADT). We prospectively evaluated LBM in a…”
Get full text

A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer by Parekh, Dipen J, Punnen, Sanoj, Sjoberg, Daniel D, Asroff, Scott W, Bailen, James L, Cochran, James S, Concepcion, Raoul, David, Richard D, Deck, Kenneth B, Dumbadze, Igor, Gambla, Michael, Grable, Michael S, Henderson, Ralph J, Karsh, Lawrence, Krisch, Evan B, Langford, Timothy D, Lin, Daniel W, McGee, Shawn M, Munoz, John J, Pieczonka, Christopher M, Rieger-Christ, Kimberley, Saltzstein, Daniel R, Scott, John W, Shore, Neal D, Sieber, Paul R, Waldmann, Todd M, Wolk, Fredrick N, Zappala, Stephen M

“…Abstract Background The 4Kscore combines measurement of four kallikreins in blood with clinical information as a measure of the probability of significant…”
Get full text

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer by Sweeney, Christopher J, Percent, Ivor J, Babu, Sunil, Cultrera, Jennifer L, Mehlhaff, Bryan A, Goodman, Oscar B, Morris, David S, Schnadig, Ian D, Albany, Costantine, Shore, Neal D, Sieber, Paul R, Guba, Susan C, Zhang, Wei, Wacheck, Volker, Donoho, Gregory P, Szpurka, Anna M, Callies, Sophie, Lin, Boris Kin, Bendell, Johanna C

“…To report efficacy and safety of samotolisib (LY3023414; PI3K/mTOR dual kinase and DNA-dependent protein kinase inhibitor) plus enzalutamide in patients with…”
Get full text

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer by Smith, Matthew R, Morton, Ronald A, Barnette, K Gary, Sieber, Paul R, Malkowicz, S Bruce, Rodriguez, Domingo, Hancock, Michael L, Steiner, Mitchell S

“…Androgen deprivation therapy is associated with fracture risk in men with prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor…”
Get more information

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer by Smith, Matthew R, Morton, Ronald A, Barnette, K Gary, Sieber, Paul R, Malkowicz, S Bruce, Rodriguez, Domingo, Hancock, Michael L, Steiner, Mitchell S

“…Androgen deprivation therapy is associated with fracture risk in men with prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor…”
Get more information

PD28-01 TESTOSTERONE LOWERING, PSA RESPONSE AND QUALITY OF LIFE IN PATIENTS WITH ADVANCED HORMONE SENSITIVE PROSTATE CANCER RECEIVING TAK-385, AN ORAL GNRH ANTAGONIST: PHASE 2 INTERIM ANALYSIS by Shore, Neal D, Bailen, James L, Pieczonka, Christopher, Saltzstein, Daniel R, Sieber, Paul R, MacLean, David B, Shi, Hongliang, Faessel, Hélène M, Lin, Huamao Mark, Zhu, Yanyan, Saad, Fred

Get full text

Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts) by Saad, Fred, Bailen, James L., Pieczonka, Christopher Michael, Saltzstein, Daniel R., Sieber, Paul R., Maclean, David B., Shi, Hongliang, Faessel, Helene M., Shore, Neal D.

“…Abstract only 200 Background: Gonadotropin-releasing hormone (GnRH) antagonists achieve rapid decrease in testosterone (T) without transient T surge seen with…”
Get full text

Treatment of bicalutamide-induced breast events by Sieber, Paul R

“…Bicalutamide is a competitive nonsteroidal androgen receptor antagonist. In the European Union and a number of other countries, bicalutamide 150 mg per day is…”
Get full text

Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer by Sieber, Paul R, Keiller, Danny L, Kahnoski, Richard J, Gallo, Jose, McFadden, Scott

“…We evaluated changes in bone mineral density (BMD), fat-free mass (FFM) and serum lipid levels during bicalutamide 150 mg monotherapy compared with medical…”
Get more information

Contemporary Prostate Biopsy Complication Rates in Community-Based Urology Practice by Sieber, Paul R, Rommel, F.M, Theodoran, Chris G, Hong, Robert D, Del Terzo, Michael A

“…Objectives To evaluate whether the increased number of rectal perforations associated with contemporary transrectal ultrasound-guided, 12-core prostate biopsy,…”
Get full text

The Role of Distal Third Radius Dual Energy X-ray Absorptiometry (DXA) and Central DXA in Evaluating for Osteopenia and Osteoporosis in Men Receiving Androgen Deprivation Therapy for Prostate Cancer by Sieber, Paul R, Rommel, F. Michael, Theodoran, Chris G, Russinko, Paul J, Woodward, Christopher A, Schimke, Leanne

“…Abstract The authors assessed the use of distal third radius dual energy X-ray absorptiometry (DXA) concomitantly with central (hip and lumbar spine) DXA to…”
Get full text

Histoplasma phimosis: An uncommon presentation of a not uncommon pathogen by ARIYANAYAGAM-BAKSH, Shashi M, BAKSH, Fabien K, CARTUN, Richard W, SIEBER, Paul R

“…Infection from Histoplasma capsulatum is usually subclinical, but it also can be disseminated in patients with a compromised immune status. Involvement of the…”
Get full text

Bladder necrosis secondary to pelvic artery embolization: case report and literature review by Sieber, P R

“…Bladder necrosis is a rare entity in the urological literature. We report a case of bladder necrosis secondary to pelvic artery embolization to control…”
Get more information

Central DXA and Peripheral DXA Should Be Routine In The Evaluation of Men With Prostate Cancer During Androgen-Deprivation Therapy by Sieber, Paul R., MD, CCD, Schimke, Leanne, CUNP, Rommel, F. Michael, MD, Theodoran, Chris G., DO, d Hong, Robert, Del Terzo, Michael, Russinko, Paul J, Woodard, Christopher A

Get full text

Enzalutamide combination treatment (tx) suspension in men with high-risk biochemically recurrent (BCR) prostate cancer: Outcomes from EMBARK by Freedland, Stephen J., Sieber, Paul R., Gleave, Martin, De Giorgi, Ugo, Mehlhaff, Bryan Allyn, Danila, Daniel Costin, Dunshee, Curtis, Lallas, Costas D., Pliskin, Marc, Tang, Yiyun, Haas, Gabriel P., Rosales, Matt, Tarazi, Jamal Christo Christo, Zohren, Fabian, Russell, David, Shore, Neal D.

“…156 Background: The 3-arm EMBARK trial found statistically superior and clinically meaningful improvements in metastasis-free survival (MFS) with enzalutamide…”
Get full text

Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study by Shore, Neal D., Sieber, Paul R., Gleave, Martin, De Giorgi, Ugo, Mehlhaff, Bryan Allyn, Danila, Daniel Costin, Dunshee, Curtis, Lallas, Costas D., Pliskin, Marc, Tang, Yiyun, Haas, Gabriel P., Rosales, Matt, Tarazi, Jamal Christo Christo, Zohren, Fabian, Russell, David, Freedland, Stephen J.

“…15 Background: In the 3-arm EMBARK trial, enzalutamide (enza) + leuprolide acetate (leuprolide) and enza monotherapy (mono) showed statistically superior and…”
Get full text

Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO‐IMPACT study by Gore, John L., du Plessis, Marguerite, Santiago‐Jiménez, María, Yousefi, Kasra, Thompson, Darby J. S., Karsh, Lawrence, Lane, Brian R., Franks, Michael, Chen, David Y. T., Bandyk, Mark, Bianco, Fernando J., Brown, Gordon, Clark, William, Kibel, Adam S., Kim, Hyung L., Lowrance, William, Manoharan, Murugesan, Maroni, Paul, Perrapato, Scott, Sieber, Paul, Trabulsi, Edouard J., Waterhouse, Robert, Davicioni, Elai, Lotan, Yair, Lin, Daniel W.

“…BACKGROUND Patients with prostate cancer and their providers face uncertainty as they consider adjuvant radiotherapy (ART) or salvage radiotherapy (SRT) after…”
Get full text

A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641) by Chi, Kim N., Rathkopf, Dana E., Attard, Gerhardt, Smith, Matthew Raymond, Efstathiou, Eleni, Olmos, David, Small, Eric Jay, Lee, Ji Youl, Sieber, Paul R., Dunshee, Curtis, Ricci, Deborah S., Simon, Jason S., Zhao, Xin, Kothari, Nishi, Cheng, Shinta, Sandhu, Shahneen Kaur

“…Abstract only TPS257 Background: Preclinical data suggest synergistic antitumor activity when the PARP inhibitor (PARPi) niraparib is combined with the…”
Get full text

Real-world study of enzalutamide and abiraterone acetate (with prednisone) tolerability (REAAcT): Results by Shore, Neal D., Saltzstein, Daniel R., Sieber, Paul R., Mehlhaff, Bryan, Gervasi, Lawrence, Phillips, Jennifer, Wong, Yu-Ning, Pei, Huiling, McGowan, Tracy

“…Abstract only 296 Background: Enzalutamide (E) and abiraterone acetate with prednisone (AAP) are approved for treatment (tx) of metastatic castration resistant…”
Get full text

Emerging Therapeutic for the Treatment of Skeletal-related Events Associated With Metastatic Castrate-resistant Prostate Cancer by Sieber, Paul R

“…Prostate cancer is the most prevalent cancer in US and European men and the second leading cause of cancer death in those populations. It is somewhat unique in…”
Get full text